The most widely used treatment for CML is Imatinib, an inhibitor of BCR-ABL tyrosine kinase, a specific inhibitor of the BCR-ABL fusion protein, commonly referred to as a tyrosine kinase inhibitor (TKI) [6, 9–12]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.